Curator Dashboard

A graphic, interactive program to map quantitative trait loci using intercrosses, backcrosses or recombinant inbred strains in experimental plants or animals. A completely rewritten cross-platform version of Map Manager QT with enhanced analysis functions. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

European Commission''s primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Software R package that provides comprehensive computational pipeline for predicting survival probabilities and risk groups in cancer patients. Includes dedicated modules to perform key steps such as data preprocessing, training/test splitting, and normalization.

• Resource
• RRID
• 8 months ago - submitted by Harpreet Kaur

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. Software application that draws genetic linkage maps on PC same as what MAPMAKER does on Mac. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A government granting agency which consults with partnered programs through national authorities and food safety agencies. EFSA organizes its annual and multi-annual work program according to priorities agreed with the European Commission and other partners, taking into account available resources. EFSA staff may also produce scientific outputs on behalf of the agency, such as peer reviews of the assessment of active substances in pesticides, or responses to urgent requests for advice. EFSA staff also monitor and analyze information and data on biological hazards, chemical contaminants, food consumption and emerging risks.

• Resource
• SciCrunch
• 13 years ago - submitted by Andrea Stagg

Core offers light microscopy and imaging services. Provides access to and training on various confocal microscopes.

• Resource
• RRID
• 7 months ago - by Anonymous

A phenotypically rich neuroimaging sample, consisting of data obtained from individuals between the ages of 4 and 85 years-old. All individuals included in the sample undergo semi-structured diagnostic psychiatric interviews, and complete a battery of psychiatric, cognitive and behavioral assessments in order to provide comprehensive phenotypic information for the purpose of exploring brain / behavior relationships.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Initiative to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by initiating and managing consortia composed of the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. IMI is a public-private partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), with a timeframe separated into two phases (2008-2013, 2014-2024) that are each defined by unique research agendas. The first phase (2008 2013) had four pillars that defined the focus of its research agenda: * Predicting safety: evaluating the safety of a compound during the pre-clinical phase of the development process and the later phases in clinical development. * Predicting efficacy: improving the ability to predict how a drug will interact in humans and how it may produce a change in function. * Knowledge management: utilization of information and data for predicting safety and efficacy. * Education and training: closing existing training gaps in the drug development process. Some of the consortia managed under IMI focused on specific health issues while others focused on broader challenges in drug development. Additionally, IMI launched a number of education and training projects during its first phases. The goal of the second phase (IMI2, 2014-2024) is to develop next generation vaccines and drugs. The focus is on delivering the right prevention and treatment for the right patient at the right time. There is a strong focus on the development of new medicines with an emphasis on tools and methods that accelerate patient access to new medicines. IMI2's agenda can be defined by four axes of research: * target validation and biomarker research (efficacy and safety) * adoption of innovative clinical trial paradigms * innovative medicines * patient-tailored adherence programs As part of its distinct goals, IMI2 aims to deliver: * 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in five years; * new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer's disease.

• Organization
• Consortia-pedia, a FasterCures Project
• 13 years ago - by Anonymous

On-line viewer for human striatum slide-tags spatial transcriptomics (10X Chromium 5' GEX) data set generated by the Macosko Lab comprising ~1.1 million cells from 19 human striatum donors.

• Resource
• dkNET
• 7 months ago - submitted by Maryann Martone

A fully automated processing pipeline for cortical analysis of structural MR images at a resolution of up to 400������m, including skull stripping, whole brain segmentation, cortical extraction, surface inflation and mapping, as well as dedicated tools for profile estimation across the cortical thickness. The tools are released as a set of plug-ins for the MIPAV software package and the JIST pipeline environment. They are therefore cross-platform and compatible with a wide variety of file formats.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Coeducational public research university in West Virginia. Its undergraduate colleges include business, education, arts and media, health professions, information technology, liberal arts, and science. Its graduate colleges include schools of medicine and pharmacy.

• Organization
• SciCrunch
• 17 years ago - submitted by Christie Wang

Core provides investigators in the Western New York area with genetically modified animals for their research through gene targeting and transgenic methodologies.

• Resource
• SciCrunch
• 7 months ago - submitted by Edyta Vieth

A FSL package for the comprehensive management of large-scale multi-site fMRI projects, including data storage, retrieval, calibration, analysis, multi-modal integration, and quality control.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

A Research as a Service (RaaS) Company founded by a Clinical Pharmacologist and Neuropsychiatrist that offers to its partners (health products industries and public research), 3 platforms: * Clinical research (CRO and SMO) * Scientific & regulatory consulting * Online surveys (Web portal) Their Research & Development profile allows them to propose innovative concepts such as : * Patient-Leader studies * Translational research studies (fMRI, innovative biomarkers, modeling, ...) * Behavioral parameters as biomarkers studies Qualissima also proposes proof of concept studies, proof of activities studies, medical devices studies and observational studies.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

Cancer genomics project management and data sharing support facility.

• Resource
• RRID
• 7 months ago - by Anonymous

A set of MATLAB scripts for analysis of networks derived from neuroimaging data. Some of these scripts are entirely original, while some are adapted (or just copied) from the Brain Connectivity Toolbox (https://sites.google.com/a/brain-connectivity-toolbox.net/bct) The source code is available via git: git clone ssh://user

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Commercial ogranization which provides molecular and drug discovery software and services to researchers. American software company that develops chemical simulation software for use in pharmaceutical, biotechnology, and materials science research. Provides products ranging from general molecular modeling programs to a full suite of chemical simulation and drug design software, including ligand- and structure-based methods.

• Resource
• SciCrunch
• 10 years ago - submitted by Kristen Jensen

Provides advanced resources in structural biology. Offers access to instruments, including multiple transmission electron microscopes (TEMs) and cryo-FIB/SEM systems. Trains scientists, from beginners to experienced users, on sample preparation (plunge/high-pressure freezers) and advanced EM techniques. Helps researchers solve the 3D structures of proteins and cellular components at atomic resolution.

• Resource
• RRID
• 6 months ago - submitted by Edward Eng

Data set of an AFNI GroupInCorr session for multi-echo independent component regression (ME-ICR) for a cohort of 52 subjects. This dataset provides a high-quality atlas of seed-based functional connectivity with strong statistical conditioning.

• Resource
• SciCrunch
• 14 years ago - by Anonymous

European website providing information about orphan drugs and rare diseases. It contains content both for physicians and for patients. Reference portal for rare diseases and orphan drugs to help improve diagnosis, care and treatment of patients with rare diseases.

• Resource
• SciCrunch
• 17 years ago - by Anonymous